Catégories principales: SubCyclo

Dr Pieter Gouws

It is safe to say that we now have a treatment modality available in SubCyclo with an excellent side effect profile that leaves us to think about how to best use this technology and in which areas we can use this gentler form of treatment.

Read More »

Dr Francesco Oddone

I am convinced that ciliary body transillumination on patients undergoing SubCyclo procedures offers benefits not only in the optimal probe placement but also inthe therapeutic outcome.

Read More »

Dr Jaromir Wasyluk

In 2021, SLT laser therapy should be considered as a preferred first line treatment for glaucoma treatment and SubCyclo favored as an alternative treatment option to surgery

Read More »

Subliminal Cyclophotocoagulation

Glaucoma is a leading cause of irreversible blindness affecting approximately 60 million people globally 40 years of age and older.􀄦 Glaucoma is a disease that cannot be ignored, and the need for signi􀃶cant changes in how we diagnose, manage, and treat must be examined and applied whenever possible.

Read More »

Ranking Laser in Glaucoma Treatment

Glaucoma management has traditionally taken a stepped approach based on the level of risk involved. The low-risk treatment option is medication. Next are laser/selective laser trabeculoplasty (SLT), MIGS, and incisional surgery. It ends with the highest risk option of cyclodestructive procedures.

Read More »

Subliminal Diode Treatment of the Ciliary Bodies by Transscleral Cyclophotocoagulation with a 31.3% Duty Cycle in the Treatment of Refractory Glaucoma: Safety and Efficacy

Micropulse Transscleral diode laser cyclophotocoagulation (MP-TSCPC) is an established method of treatment for refractory glaucoma. This study evaluates the efficacy in terms of reduction in intraocular pressure and/or treatment amount, and safety and side effects of the ciliary bodies using a subthreshold laser with a duty cycle of 31.3% with Supra 810 nm Subliminal Quantel Medical, at one year in patients with refractory glaucoma.

Read More »
Share this page by email
Share this page on facebook
Share this page on twitter
Share this page on linkedin